Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent
ConditionCoronary Artery Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorAsan Medical Center
About this trial
Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)
Hypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS/OCT could act as an essential criterion for decision making for tailored antithrombotic strategy)
Eligibility criteria
Qualifiers
Men or women ≥19 years
Typical chest pain or objective evidence of myocardial ischemia suitable for PCI
Significant de novo coronary artery lesions suitable for DES implantation
Patients who underwent optimized stent implantation either by IVUS or OCT
Disqualifiers
Extreme angulation (≥90°) proximal to or within the target lesion.
Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.
Heavy calcification proximal to or within the target lesion.
In-stent restenosis
Trial design
Treatments tested in this trial
- aspirin
Treatment groups
3,944 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov